Junshi Bio Completes $50 Million Investment in US Partner, Coherus
publication date: Apr 20, 2021
Shanghai Junshi Bio completed its $50 million investment into its US partner, Coherus Biosciences. In February, the two companies announced a $1.1 billion agreement, including a $150 million upfront payment to Junshi, that gives Coherus the right to commercialize Junshi's anti-PD-1 antibody in the US and Canada. One day later, Junshi announced it would make a $50 million investment in Coherus. Junshi's Tuoyi (toripalimab) was the first China-developed anti-PD-1 antibody approved in China. More details....
Stock Symbols: (HK: 1877; SHA: 688180) (NSDQ:CHRS)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.